Results 41 to 50 of about 104,915 (286)

Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA [PDF]

, 2006
Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA\u27s pharmaceutical data and the resultant restrictions on open discourse.
Ankelhed, Daniel, Hansson, Anders, Helmersson, Anders   +2 more
core   +2 more sources

Medical treatment of ascites in cirrhosis [PDF]

, 1993
Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired cardiovascular or respiratory function and potential for infection. Treatment of ‘simple’ ascites (moderate fluid accumulation, serum albumin
Alexander L. Gerbes, Bernardi, Bichet, Bosch, Broekhuysen, Caramelo, Conn, DiBona, Epstein, Faloon, Fogel, Fuller, Ganger, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Ginès, Gregory, Guarner, Henriksen, Hoermann, Jüngst, Karnad, Keppler, Laffi, Lenz, Levy, Moore, Perez-Ayuso, Petrillo, Pockros, Ring-Larsen, Schrier, Schölmerich, Shear, Sherlock   +41 more
core   +1 more source

Mass balance and pharmacokinetics of an oral dose of 14C‐napabucasin in healthy adult male subjects

Pharmacology Research & Perspectives, 2021
This phase 1, open‐label study assessed14C‐napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites (primary objectives); safety/tolerability were also evaluated.
Xiaoshu Dai, Michael D. Karol, Matthew Hitron, Marjie L. Hard, John Evan Blanchard, Nicola C. J. E. Eraut, Natalie Rich, Brandon T. Gufford   +7 more
doaj   +1 more source

Real‐World Pediatric Blinatumomab Administration: Access to Outpatient Care Delivery and Impact of a Hospital‐Dispensed Model

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab has been shown to be highly effective for patients with pediatric B‐ALL and has recently become standard of care therapy. Due to its past use in the clinical trial setting, there is limited information available about real‐world administration.
Katelyn Oranges, Kelly A. Duffy, Sara McDonough, Evelyn Kurpiewski, R. Jennifer Randall, Allison Barz Leahy, Haley M. Newman, Joyce P. Lee, Stephen P. Hunger, Anne F. Reilly, David T. Teachey, Susan R. Rheingold, Daniel J. Zheng   +12 more
wiley   +1 more source

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

Pharmaceuticals, 2021
Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms.
Barbara Miziak, Barbara Błaszczyk, Stanisław J. Czuczwar   +2 more
doaj   +1 more source

How developing world concerns need to be part of drug development plans: A case study of four emerging antiretrovirals [PDF]

, 2008
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries.
Alexandra Calmy, Cahn, Cahn, Chokshi, Cleary, Cohen, Dayam, Esté, Ford, Ford, Jens van Roey, Khoo, Marzolini, Moran, Nathan, Nathan Ford, Pinheiro, Pozniak, Saag, Tido von Schoen-Angerer, Woodfall, World Health Organization, Yeni   +22 more
core   +3 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19 [PDF]

Folia Medica, 2020
Introduction: Despite clinical trials, there are still no approved specific therapies or any vaccine against COVID-19. The only option available is using investigational drugs for compassionate use.
Nigyar Dzhafer, Jannis V. Papathanasiou
doaj   +3 more sources

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. [PDF]

, 2016
The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery.
Alturkmani, Hani, Baltezor, Michael, Butte, Atul J, Chen, Bin, Flynn, Colleen A, Godwin, Andrew K, Hyter, Stephen, Ma, Yan, Neville, Kathleen A, Pessetto, Ziyan Y, Rosenthal, Howard G, Weir, Scott J   +11 more
core   +3 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source